Fennec Pharmaceuticals Inc FENC.OQ FENC.O is expected to show a fall in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
The Research Triangle Park North Carolina-based company is expected to report a 67.8% decrease in revenue to $8.181 million from $25.38 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fennec Pharmaceuticals Inc is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00, above its last closing price of $6.21.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.44 | 0.17 | -0.06 | Missed | -136.1 |
Sep. 30 2024 | -0.14 | -0.09 | -0.21 | Missed | -133.3 |
Jun. 30 2024 | -0.11 | -0.03 | -0.20 | Missed | -552.1 |
Mar. 31 2024 | 0.30 | 0.26 | 0.47 | Beat | 79.4 |
Dec. 31 2023 | -0.05 | -0.02 | -0.10 | Missed | -410.2 |
Sep. 30 2023 | -0.12 | -0.12 | -0.07 | Beat | 41.7 |
Jun. 30 2023 | -0.17 | -0.16 | -0.21 | Missed | -34.2 |
Mar. 31 2023 | -0.21 | -0.21 | -0.23 | Missed | -9.6 |
This summary was machine generated May 9 at 14:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)